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Background: Statins exert pleiotropic anti-inflammatory and
immune-modulatory effects, which might translate into antiviral
activity. We evaluated whether reported current statin exposure is
associated with lower levels of markers of HIV persistence and
immune activation/inflammation.
Methods: We compared levels of markers of HIV viral persistence
[cell-associated HIV RNA (CA-RNA), CA-DNA, and single copy
assay plasma HIV RNA] and immune activation/inflammation (IL-6,
IP-10, neopterin, sCD14, sCD163, and TNF-alpha) between statin
users and nonusers among participants of ACTG A5321 who
initiated antiretroviral therapy (ART) during chronic infection and
maintained virologic suppression (HIV-1 RNA levels #50
copies/mL) for $3 years.
Results: A total of 303 participants were analyzed. Median time on
the current statin was 2.9 years (1.2–5.1). There were no differences
between statin users and nonusers in levels of CA-DNA (median 650
vs. 540 copies/106 CD4+ T cells; P = 0.58), CA-RNA (53 vs. 37
copies/106 CD4+ T cells; P = 0.12), or single copy assay (0.4 vs. 0.4
copies/mL; P = 0.45). Similarly, there were no significant differences
between statin users and nonusers in markers of inflammation/
activation, except for IP-10 (137 vs. 118 pg/mL; P = 0.028).
Findings were unchanged after adjustment for factors including pre-
ART CD4 and HIV RNA, and years on ART.
Conclusions: In this cohort of persons on long-term suppressive
ART, current statin use was not associated with lower levels of HIV
persistence or immune activation/inflammation. These results do not
support a major role for statins in reducing HIV persistence, although
an early transient effect cannot be excluded. Prospective, randomized
studies are needed to confirm these findings.
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INTRODUCTION
HMG-coenzyme A reductase inhibitors (statins) exert
pleiotropic anti-inflammatory1 and immune-modulatory ef-
fects.2 Their inhibition of mevalonate metabolism, which also
regulates T-lymphocyte biology, could potentially enhance
immune response against invading pathogens,3 and their
inhibition of the induction of major histocompatibility
complex class II (MHC-II) expression by interferon-gamma
(IFN-g) leads to reduction of T-cell activation.2
Likely as a result of these effects, statins have been
found to have in vitro antiviral activity against human
cytomegalovirus,4 dengue virus,5,6 and HIV-1.7 Several
specific anti-HIV effects of statins have been observed
in vitro, including induction of resistance of CD4 T cells to
HIV-1 infection through p21 upregulation,8 inhibition of
HIV-1 integrase LEDGF/p75-HIV-1 interaction,9 and inhibi-
tion of viral expression.7
We have shown that statin use is associated with
a reduced risk of virologic rebound in people on suppressive
antiretroviral therapy (ART) in a large cohort of HIV-infected
US Veterans.10 We hypothesized that this finding might
reflect anti-inflammatory, immunomodulatory, or direct anti-
viral effects of statins as described above, resulting in
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decreased HIV reservoir size. We therefore evaluated whether
current statin exposure is associated with lower levels of
markers of HIV persistence, immune activation,
and inflammation.
AIDS Clinical Trials Group study A5321 evaluated
longitudinal changes of markers of HIV-1 persistence in
relation to inflammation, T-cell activation, and cycling in
a large cohort of participants who had initiated ART during
chronic HIV-1 infection and had long-term (3–10+ years)
sustained suppression of plasma viremia. In that population,
we previously showed that high levels of inflammation,
immune activation, and T-cell cycling before treatment cor-
related with high levels during therapy, even after many years
of sustained virologic suppression. On the other hand, these
inflammatory markers did not correlate with markers of viral
persistence (HIV-1 DNA, cell-associated HIV-1 RNA, or
plasma HIV-1 RNA) during suppressive therapy, suggesting
that HIV-1 persistence is not driving or being driven by
inflammation or immune activation.11
It therefore remains unclear what drives persistent
inflammation and immune activation on ART, and whether
any adjunctive therapies could further decrease it. In this
study, we used samples from the A5321 cohort to evaluate
whether statin exposure is associated with lower levels of
viral persistence or inflammation/immune activation, or
whether their effects on viral persistence and inflammation/
immune activation are correlated.
METHODS
Study Population
All A5321 participants included in this analysis had
initiated ART during chronic HIV-1 infection, had achieved
virologic suppression (HIV-1 RNA levels#50 copies/mL) by
year 1 of ART, and maintained suppression with no
documented breakthroughs (consecutive HIV-1 RNA .50
copies/mL) in the 3 years before biomarker evaluation.
Participants were censored (excluded) from analyses if
they had previous use of an investigational agent that might
affect HIV reservoirs or were HCV RNA positive. Partic-
ipants were classified as statin users if they reported receiving
statins at the time of biomarker evaluation.
Paired plasma and peripheral blood mononuclear cell
(PBMC) samples were collected at A5321 study entry for
virologic and immunologic assays.
Virologic Assays
We measured 3 markers of HIV-1 persistence: un-
spliced cell-associated HIV RNA (CA-RNA), total CA-DNA,
and single copy assay (SCA) plasma HIV RNA. CA-RNA
and CA-DNA were measured by quantitative polymerase
chain reaction (qPCR) in PBMC samples using methods that
have been previously published.11 Plasma HIV RNA by SCA
was measured using previously published methods: Primers
and probes used for qPCR of HIV DNA, CA-RNA, and
plasma HIV-1 RNA were identical and targeted a conserved
region of integrase.12
HIV DNA and CA-RNA (per 106 CD4+ T cells) were
normalized by dividing the total HIV DNA or CA-RNA
copies/106 PBMC as measured by qPCR by the CD4+ T-cell
percentage from the same specimen date or closest specimen
date before or after the HIV DNA or CA-RNA results.12
Immunologic Assays
Plasma concentrations of interleukin (IL)-6, IFN-
g–inducible protein 10 (IP-10), neopterin, soluble CD14
(sCD14), soluble CD163 (sCD163), and TNF-alpha were
quantified using enzyme-linked immunosorbent assay kits,
and CD4+ and CD8+ T-cell activation was quantified from
PBMCs by multicolor flow cytometry as previously
described.11
Statistical Analysis
The Wilcoxon rank-sum test compared continuous
outcomes between those on a statin versus not on a statin at
the time of biomarker measurement, analyzing results below
assay limit as the lowest rank. The Fisher exact test compared
the dichotomous outcome (SCA $ or ,0.4 copies/mL) and
categorical variables; the signed-rank test evaluated changes
in lipids. We performed sensitivity analyses by removing
participants with previous statin use reported, but who were
not currently taking statins at A5321 entry. In addition,
regression models were used to adjust for variables correlated
with markers of HIV persistence.
RESULTS
Study Participants
A total of 303 participants who initiated ART during
chronic HIV infection and had maintained virologic suppres-
sion for $3 years were analyzed. The median age was 48
years; 82% were men; and 55% were white. At the time of
biomarker measurements, median duration of suppressive
ART exposure was 7.3 years (interquartile range: 6.1–10.1);
median CD4 count was 681/mm3 (515–864); 72 (24%)
participants reported receiving statins. The median time to
biomarker assessment was 2.9 years (1.2–5.1) on the current
statin and 4.5 years (2.7–7.4) since first statin use.
Characteristics of statin and nonstatin recipients are
presented in Table 1. Of note, statin users were older with
greater duration on ART.
A total of 16 participants classified as nonstatin users
had previous statin use, but were not taking a statin at time of
biomarker measurements. Among these participants, the
median time off statins before the measurements (since stop
of most recent statin) was 1.8 years (min: 0.1 and max: 12.0).
Markers of Viral Persistence
Median levels of biomarkers of viral persistence are
presented in Table 2.
There were no differences between statin users and
nonusers in levels of CA-DNA (median 650 vs. 540 copies/
106 CD4+ T cells; P = 0.58), CA-RNA (53 vs. 37 copies/106
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CD4+ T cells; P = 0.12), or SCA (46% vs. 54% ,0.4
copies/mL; P = 0.27). The results were similar in sensitivity
analyses excluding the 16 participants with past
statin exposure.
Findings with viral persistence were unchanged after
adjustment for the following factors: sex of participant, pre-
ART CD4 and HIV RNA, CD4 count at study A5321 entry,
HCV status, antiretroviral regimen, age, and years on ART (P
$ 0.28; P$ 0.07; and P$ 0.09 for CA-DNA, CA-RNA, and
SCA, respectively).
Markers of Inflammation/Immune Activation
Median levels of biomarkers of inflammation and
immune activation are also presented in Table 2.
There were no significant differences between statin
users and nonusers in markers of inflammation/activation,
except for IP-10, which had higher values in statin users than
nonusers (137 vs. 118 pg/mL, respectively; P = 0.028). This
association with IP-10 remained (P , 0.05) after adjustment
for confounders other than age; after adjustment for age, IP-
10 levels remained higher, but the effect was attenuated (P
= 0.12).
Lipid Changes
To address the possibility that the absence of statin
effects on viral persistence and inflammation biomarkers was
due to nonadherence, changes in fasting low-density lipopro-
tein (LDL) levels were examined. Among the 49 statin users
TABLE 1. Participant Characteristics
On Statin at A5321 Entry
Yes (N = 72) No (N = 231) Total (N = 303) P*
Age at A5321 entry (yr)
Median (Q1–Q3) 53 (49–60) 46 (39–53) 48 (41–54) ,0.001
Sex (%male) 61 (85%) 187 (81%) 248 (82%) 0.60
Race/ethnicity
White non-Hispanic 46 (64%) 122 (53%) 168 (55%) 0.34
Black non-Hispanic 10 (14%) 51 (22%) 61 (20%)
Hispanic (regardless of race) 14 (19%) 52 (23%) 66 (22%)
Other 2 (3%) 6 (3%) 8 (3%)
Smoking (%cigarette smoker at A5321 entry) 15 (21%) 55 (24%) 70 (23%) 0.64
Diabetes diagnosis before A5321 entry 10 (14%) 7 (3%) 17 (6%) 0.002
Intravenous drug use at A5321 entry
Current 0 (0%) 0 (0%) 0 (0%) 0.31
Previous 1 (1%) 11 (5%) 12 (4%)
Never 71 (99%) 220 (95%) 291 (96%)
ARV regimen at A532 entry
NNRTI-based 45 (63%) 113 (49%) 158 (52%) 0.22
PI-Based 16 (22%) 66 (29%) 82 (27%)
InSTI-based 11 (15%) 51 (22%) 62 (20%)
Other 0 (0%) 1 (0%) 1 (0%)
Years on ART at A5321 entry
Median (Q1–Q3) 8.1 (6.6–12.3) 7.3 (4.8–8.5) 7.3 (6.1–10.1) 0.002
Pre-ART CD4+ T-cell count (cells/mm3)
Median (Q1–Q3) 286 (110–414) 254 (114–369) 258 (113–374) 0.27
A5321 entry CD4+ T-cell count (cells/mm3)
Median (Q1–Q3) 737 (542–935) 665 (505–840) 681 (515–864) 0.038
Pre-ART plasma HIV-1 RNA (log10 copies/mL)
Median (Q1–Q3) 4.6 (4.3–5.0) 4.6 (4.2–5.0) 4.6 (4.2–5.0) 0.82
A5321 entry HIV-1 RNA (copies/mL)
,40 72 (100%) 231 (100%) 303 (100%)
Statin at A5321 entry
Simvastatin 5 (7%) 0 (0%) 5 (2%)
Pravastatin 25 (35%) 0 (0%) 25 (8%)
Atorvastatin 27 (38%) 0 (0%) 27 (9%)
Rosuvastatin 14 (19%) 0 (0%) 14 (5%)
Ezetimibe/simvastatin 1 (1%) 0 (0%) 1 (0%)
*The Exact Wilcoxon test for continuous variables and the Fisher exact test for categorical variables.
ARV, antiretroviral; InSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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with measurements before and approximately 1 year after first
statin use,13 fasting LDL levels declined a median 37 mg/dL
(Q1, Q3: 18, 58; P, 0.001). Comparing levels before first statin
use to the latest available measurement (median 4 months before
the measurement of biomarkers of viral persistence), fasting
LDL levels declined a median 44 mg/dL (Q1, Q3: 15, 68; n =
60, P , 0.001) over a median 3.8 years.
DISCUSSION
Despite long-term viral suppression, elevated levels of
inflammation and immune activation persist in some ART-
treated individuals. Given its association with long-term
complications and mortality, and the fact that it might
contribute to viral persistence, this residual chronic inflam-
mation and immune activation likely represent an important
therapeutic target to improve the long-term prognosis of
people living with well-controlled HIV.
In this cohort of participants on long-term suppressive
ART, reported current statin use was not associated with
lower levels of HIV persistence or immune activation/
inflammation. The results failed to validate our hypothesis
that the observed in vitro antiviral effect of statins would
result in a decrease in HIV-1 reservoir reflected by lower
measured levels of viral persistence. They also do not support
the hypothesis that a possible effect of decreased HIV
reservoir size accounts for our reported statin association
with lower risk of virologic rebound.10 The mechanism of the
latter effect of statin use remains unexplained, but likely
reflects characteristics of individuals who use statins other
than HIV reservoir size.
We also observed a lack of association between statin
exposure and most markers of immune activation/
inflammation. In the SATURN-HIV study, there was also
no statistically significant difference between rosuvastatin
recipients and controls in changes in several markers of
systemic inflammation and coagulation—except for
lipoprotein-associated phospholipase A2—at week 24.14
However, contrary to our findings, statin recipients had
significantly greater decreases in the monocyte activation
marker soluble CD14.15 Also contrary to our findings are
those of the INTREPID study which showed that pitavastatin
use was associated with reduction in markers of monocyte
activation and arterial inflammation16 as well as proteins
involved in coagulation and oxidative stress.17 However, our
results are in line with other prospective studies that have
failed to show a benefit of anti-inflammatory and immune-
regulatory measures—including sevelamer,18 mesalamine,19
rifaximin,20 and atorvastatin21—on HIV-associated chronic
inflammation and immune activation.
Interestingly, we observed significantly higher plasma
levels of IP-10 among participants receiving statins. Although
this association could have occurred by chance given that we
performed multiple comparisons, statins have been shown to
repress dendritic cell (DC) maturation thereby inducing
tolerogenic DCs that secrete high levels of IL-10 and IP-10
and induce expansion of regulatory T cells which also secrete
IL-10.22 In the presence of IL-10, DCs in the liver, lung, and
spleen transform into regulatory DCs, which could be induced
to produce both IL-10 and IP-10.23,24
Strengths of our study include concomitant analysis of
several biomarkers of viral persistence and immune activation
and inflammation in a well-characterized cohort of HIV-
infected participants. In addition, all participants in the study
had consistently maintained virologic suppression, which
means they were likely to be adherent to their antiretrovirals;
this feature of the cohort reduces the likelihood that difference
in antiretroviral adherence between statin users and nonusers
might result in spurious associations. One limitation of the
study is that biomarker assessments were made after partic-
ipants had achieved virologic suppression on ART for
a median of over 7 years and had received statins for a median
of over 4 years. Significant declines in LDL levels after the
start of the reported statin use strongly suggests that the
absence of statin effect on markers of viral persistence,
TABLE 2. Markers of Viral Persistence and Inflammation by
Statin Use
On Statin at A5321 Entry





Median (Q1–Q3) 650 (206–1562) 540 (232–1317) 0.58
CA-RNA (cps/106 CD4+
T cells)
Median (Q1–Q3) 53 (14–198) 37 (14–125) 0.12
HIV-1 RNA through
iSCA
,0.4 cps/mL 31 (46%) 120 (54%) 0.27
If $0.4 cps/mL





Median (Q1–Q3) 1.5 (1.1–2.0) 1.4 (0.9–2.3) 0.20
IP-10 (pg/mL)
Median (Q1–Q3) 137.2 (93.2–183.7) 117.7 (84.3–156.3) 0.028
Neopterin (nMol/L)
Median (Q1–Q3) 9.4 (7.4–11.6) 9.1 (7.1–10.9) 0.20
sCD14 (ng/mL)
Median (Q1–Q3) 2036 (1548–2444) 1915 (1459–2444) 0.41
sCD163 (ng/mL)
Median (Q1–Q3) 572 (402–749) 526 (382–776) 0.43
TNF-a (pg/mL)
Median (Q1–Q3) 1.9 (1.2–3.2) 1.9 (1.1–3.3) 0.74
CD4+ T-cell activation (%
CD38+/HLA-DR+)
3.5 (2.9–4.6) 3.9 (2.9–5.5) 0.32
CD8+ T-cell activation (%
CD38+/HLA-DR+)
7.3 (4.4–15.1) 9.4 (5.7–13.9) 0.22
For markers of viral persistence, the number of participants on statins and not on
statins is 68 and 224 for HIV DNA and iSCA, and 67 and 216 for CA-RNA. For T-cell
activation, the number of participants on statins and not on statins is 24 and 75.
*The Wilcoxon test for continuous variables and the Fisher exact test for iSCA.
CA-RNA, cell-associated RNA; iSCA, SCA plasma HIV RNA.
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inflammation, and immune activation was not likely due to
poor adherence. Statins may have had transient effects after
their initiation that subsequently waned. Different statins may
also differ in their effect(s) on markers of inflammation and
immune activation.25 Also, there could be a dose-dependent
effect on the measured markers. We did not record dose of
statins received. Furthermore, effect of specific statins and/or
doses could not be assessed on such a small sample size.
Prospective, randomized studies, such as REPRIEVE
(ClinicalTrials.gov Identifier: NCT02344290), could better
assess the effect of specific statins on chronic inflammation/
immune activation and HIV persistence.
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